{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "CBLL",
  "name": "CeriBell, Inc.",
  "url": "https://frontierpicks.com/dossiers/CBLL/",
  "json_url": "https://frontierpicks.com/dossiers/CBLL.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "graded_conviction": null,
  "archetype": {
    "code": "a7",
    "n": 7
  },
  "current_thesis": "Ceribell’s reimbursement-backed delirium expansion needs a Q4 2026 commercial launch and a weekly close above $24.89 to confirm the next leg. A weekly close below $21.50 invalidates the price thesis; the 2026-10-01 payment start alone does not establish adoption.",
  "invalidation_trigger": "A weekly close below $21.50 ends the continuation thesis, retaining the research threshold published on 2026-08-30. A commercial launch postponed beyond Q4 2026 would separately break the timing premise.",
  "catalyst_date": "2026-10-01",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "medtech-diagnostics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Ceribell’s 2026-05-11 Form 10-Q states that NTAP eligibility lasts no more than three years for a specific indication; this reimbursement is temporary."
  ],
  "body_markdown": "## Current Thesis\n\nCeribell’s reimbursement-backed delirium expansion needs a Q4 2026 commercial launch and a weekly close above the market’s $24.89 reference high to confirm the next leg; a weekly close below $21.50 invalidates the price thesis. The Centers for Medicare & Medicaid Services (CMS) granted a New Technology Add-on Payment (NTAP) of up to $2,171 per eligible Medicare inpatient case on 2026-08-03, effective 2026-10-01. That establishes hospital reimbursement eligibility; it does not establish Ceribell orders. [Company reimbursement announcement](https://investors.ceribell.com/news-releases/news-release-details/ceribell-secures-cms-new-technology-add-payment-ntap).\n\nThe August 30 assessment of analyst silence is now stale: Investing.com reported on 2026-09-11 that BTIG reiterated its $30 price target and discussed a physician survey. The inference remains that the narrative is maturing — September coverage revisits the August reimbursement story at an unchanged BTIG target, while the 2026-09-11 adjusted close of $23.63 remains below the supplied $24.89 reference high. This evidence establishes renewed coverage, without establishing broader participation. [September 11 BTIG report](https://ca.investing.com/news/stock-market-news/btig-reiterates-ceribell-stock-rating-at-buy-30-price-target-93CH-4836343).\n\n## Bull Case\n\n- **Core revenue supports the expansion.** Ceribell reported Q2 2026 revenue of $28.1 million, up 33% year over year, and 712 active accounts on 2026-08-10. Management raised full-year revenue guidance to $114–117 million; a subsequent reduction below that range would weaken this operating support. [Q2 results](https://investors.ceribell.com/news-releases/news-release-details/ceribell-reports-second-quarter-2026-financial-results).\n- **Reimbursement has an effective date.** The 2026-08-03 announcement specifies 2026-10-01 for the delirium NTAP. The inference is that payment eligibility supports commercialization; failure to launch within management’s Q4 2026 window would break the timing case. [NTAP announcement](https://investors.ceribell.com/news-releases/news-release-details/ceribell-secures-cms-new-technology-add-payment-ntap).\n- **Existing users expressed interest.** Investing.com’s 2026-09-11 account of BTIG’s survey says 79% of 24 surveyed US Ceribell users planned to adopt the delirium monitor. This measures stated intentions among existing users; the sample is too small to support a claim about broad hospital adoption. [BTIG survey coverage](https://ca.investing.com/news/stock-market-news/btig-reiterates-ceribell-stock-rating-at-buy-30-price-target-93CH-4836343).\n\n## Bear Case\n\n- **Spending outpaced revenue growth.** The 2026-08-10 results reported Q2 operating expenses of $45.9 million, up 37% year over year, and a net loss of $19.3 million. Another quarter with expense growth exceeding revenue growth would confirm that operating leverage remains absent. [Q2 results](https://investors.ceribell.com/news-releases/news-release-details/ceribell-reports-second-quarter-2026-financial-results).\n- **Reported margin included temporary help.** Management attributed part of Q2 2026’s 92% gross margin to one-time tariff refunds in the 2026-08-10 reporting. A subsequent margin below that quarter’s level would confirm that the reported peak was not sustained. [Q2 results](https://investors.ceribell.com/news-releases/news-release-details/ceribell-reports-second-quarter-2026-financial-results).\n- **Hospital payment differs from company revenue.** Ceribell’s 2026-05-11 quarterly filing says the company invoices healthcare providers rather than third-party payers and warns that reimbursement constraints can impede adoption. Payment eligibility beginning 2026-10-01 without a Q4 commercial launch would leave the conversion thesis unfulfilled. [Q1 Form 10-Q](https://investors.ceribell.com/static-files/08138815-3d98-41bc-bed9-8fb6f050ff40).\n\n## Setup & Price Structure\n\nThe supplied adjusted market series records a $23.63 close on 2026-09-11, 5.1% below its $24.89 52-week high, with a three-month price increase of 27.9%. Its 14-period relative strength index (RSI) reads 43.5. Those measurements show a positive medium-term price change alongside weaker recent momentum; they do not establish a completed base.\n\nThe $21.50 threshold is the research invalidation level published on 2026-08-30, retained for continuity. The available price context does not independently establish it as a moving average or a repeatedly tested support shelf. A weekly close above the supplied $24.89 high would meet the price-confirmation condition; a weekly close below $21.50 would end this continuation thesis.\n\nThe positioning evidence remains limited. The August Form 4 record includes executive open-market sales on 2026-08-19 and tax-withholding dispositions on 2026-08-21; those transaction types cannot be treated as equivalent discretionary signals. BTIG’s 2026-09-11 reiteration establishes analyst attention, while current short-interest, retail-flow and moving-average measurements are missing. Neither crowding nor an absence of crowding is established.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-10-01 — Delirium reimbursement becomes effective.** Ceribell’s 2026-08-03 announcement specifies the start of the NTAP of up to $2,171 per eligible Medicare inpatient case. This resolves the payment timetable, not the commercial launch or order volume. [Company announcement](https://investors.ceribell.com/news-releases/news-release-details/ceribell-secures-cms-new-technology-add-payment-ntap).\n\nAs checked on 2026-09-13, the company’s events page provides no confirmed upcoming earnings date. Management’s Q4 2026 launch window remains the later commercial test, but no day-level launch date is established in the available evidence. [Company events](https://investors.ceribell.com/news-events/events), [September 11 launch coverage](https://ca.investing.com/news/stock-market-news/btig-reiterates-ceribell-stock-rating-at-buy-30-price-target-93CH-4836343).\n\n## What Would Change Our Mind\n\nFailure of the August continuation structure would end the market thesis: a weekly close below $21.50 breaches the threshold published on 2026-08-30. Commercially, an announced postponement beyond Q4 2026 or a reduction below the $114–117 million full-year revenue guidance issued on 2026-08-10 would break a supporting premise.\n\nThe positive case is defined as a confirmed Q4 2026 commercial launch accompanied by a weekly close above the supplied $24.89 reference high before the invalidation close occurs. The 2026-09-11 BTIG survey supports interest but cannot substitute for the launch; the 2026-10-01 payment date alone is insufficient.\n\n## Correlation Notes\n\nThis remains a single-company medtech setup. The dated drivers are Ceribell’s 2026-08-03 reimbursement announcement and 2026-08-10 operating results; no peer-return series or measured sector correlation accompanies the 2026-09-11 price evidence. A claim that a healthcare group move confirms this thesis is therefore unsupported.\n\nCeribell’s 2026-08-03 announcement describes seizure and delirium monitoring on the same platform. That establishes shared product exposure, but it provides no measured stock-price correlation with other diagnostic companies. [Platform description](https://investors.ceribell.com/news-releases/news-release-details/ceribell-secures-cms-new-technology-add-payment-ntap).",
  "first_seen": "2026-08-21",
  "last_analyzed": "2026-09-13T00:57:48+00:00",
  "last_synthesized": "2026-09-13",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}